Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Lung Cancer

  Free Subscription


Articles published in J Nucl Med

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    March 2017
  1. USMANIJ EA, Natroshvili T, Timmer-Bonte JN, Oyen WJ, et al
    The predictive value of early in-treatment FDG-PET/CT response to chemotherapy in combination with bevacizumab in advanced non-squamous non-small cell lung cancer.
    J Nucl Med. 2017 Mar 23. pii: jnumed.116.185314. doi: 10.2967/jnumed.116.185314.
    PubMed     Text format     Abstract available


  2. VERA P, Thureau S, Chaumet-Riffaud P, Modzelewski R, et al
    Phase II study of a radiotherapy total dose increase in hypoxic lesions identified by F-miso PET/CT in patients with non-small cell lung carcinoma [RTEP5 study].
    J Nucl Med. 2017 Mar 2. pii: jnumed.116.188367. doi: 10.2967/jnumed.116.188367.
    PubMed     Text format     Abstract available


    February 2017
  3. SCHWARTZ J, Grkovski M, Rimner A, Schoder H, et al
    Pharmacokinetic Analysis of Dynamic 18F-FMISO PET Data in Non-small Cell Lung Cancer.
    J Nucl Med. 2017 Feb 23. pii: jnumed.116.180422. doi: 10.2967/jnumed.116.180422.
    PubMed     Text format     Abstract available


    October 2016
  4. VALTORTA S, Moro M, Prisinzano G, Bertolini G, et al
    Metabolic evaluation of non-small cell lung cancer patient-derived xenografts models using [18F]FDG PET: potential tools for early therapy response.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.176404.
    PubMed     Text format     Abstract available


  5. DESSEROIT MC, Tixier F, Weber WA, Siegel BA, et al
    Reliability of PET/CT shape and heterogeneity features in functional and morphological components of Non-Small Cell Lung Cancer tumors: a repeatability analysis in a prospective multi-center cohort.
    J Nucl Med. 2016 Oct 20. pii: jnumed.116.180919.
    PubMed     Text format     Abstract available


  6. FAYAD H, Schmidt H, Kuestner T, Visvikis D, et al
    4D MR and attenuation map generation in PET/MR imaging using 4D PET derived deformation matrices: a feasibility study for lung cancer applications.
    J Nucl Med. 2016 Oct 13. pii: jnumed.116.178947.
    PubMed     Text format     Abstract available


    September 2016
  7. SCHAEFFERKOETTER JD, Yan J, Soderlund TA, Townsend DW, et al
    Quantitative Accuracy and Lesion Detectability of Low-Dose FDG-PET for Lung Cancer Screening.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.177592.
    PubMed     Text format     Abstract available


  8. YIP SS, Kim J, Coroller T, Parmar C, et al
    Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer.
    J Nucl Med. 2016 Sep 29. pii: jnumed.116.181826.
    PubMed     Text format     Abstract available


    June 2016
  9. GROOTJANS W, Tixier F, van der Vos CS, Vriens D, et al
    The impact of optimal respiratory gating and image noise on evaluation of intra-tumor heterogeneity in 18F-FDG positron emission tomography imaging of lung cancer.
    J Nucl Med. 2016 Jun 9. pii: jnumed.116.173112.
    PubMed     Text format     Abstract available


    April 2016
  10. KRAMER GM, Frings V, Hoetjes N, Hoekstra OS, et al
    Repeatability of Quantitative Whole Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    J Nucl Med. 2016 Apr 21. pii: jnumed.115.170225.
    PubMed     Text format     Abstract available


    March 2016
  11. TIXIER F, Vriens D, Cheze-Le Rest C, Hatt M, et al
    Comparison of tumor uptake heterogeneity characterization between static and parametric 18F-FDG PET images in Non-Small Cell Lung Cancer.
    J Nucl Med. 2016 Mar 10. pii: jnumed.115.166918.
    PubMed     Text format     Abstract available


    February 2016
  12. OHRI N, Duan F, Snyder BS, Wei B, et al
    Pretreatment 18FDG-PET Textural Features in Locally Advanced Non-Small Cell Lung Cancer: Secondary Analysis of ACRIN 6668/RTOG 0235.
    J Nucl Med. 2016 Feb 11. pii: jnumed.115.166934.
    PubMed     Text format     Abstract available


  13. SHEIKHBAHAEI S, Mena E, Marcus C, Wray R, et al
    18F-Fluorodeoxyglucose PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients.
    J Nucl Med. 2016 Feb 2. pii: jnumed.115.165480.
    PubMed     Text format     Abstract available


    January 2016
  14. BURGER IA, Casanova R, Steiger S, Husmann L, et al
    FDG-PET/CT of non-small cell lung carcinoma under neo-adjuvant chemotherapy: background based adaptive volume metrics outperform TLG and MTV in predicting histopathological response.
    J Nucl Med. 2016 Jan 28. pii: jnumed.115.167684.
    PubMed     Text format     Abstract available


  15. SAWICKI LM, Grueneisen J, Buchbender C, Schaarschmidt BM, et al
    Comparative performance of 18F-FDG PET/MRI and 18F-FDG PET/CT regarding detection and characterization of pulmonary lesions in 121 oncologic patients.
    J Nucl Med. 2016 Jan 7. pii: jnumed.115.167486.
    PubMed     Text format     Abstract available


    December 2015
  16. KANG F, Wang S, Tian F, Zhao M, et al
    Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer (NSCLC) and Tuberculosis Patients.
    J Nucl Med. 2015 Dec 30. pii: jnumed.115.167924.
    PubMed     Text format     Abstract available


  17. IQBAL R, Kramer GM, Verwer EE, Huisman MC, et al
    Multiparametric analysis of the relationship between tumor hypoxia and perfusion using 18F-FAZA and 15O-H2O PET.
    J Nucl Med. 2015 Dec 10. pii: jnumed.115.166579.
    PubMed     Text format     Abstract available


  18. PRIOR JO, Peguret N, Pomoni A, Pappon M, et al
    Reduction of Respiratory Motion during PET/CT by Pulsatile-Flow Ventilation (PFV-PET/CT): A First Clinical Evaluation.
    J Nucl Med. 2015 Dec 3. pii: jnumed.115.163386.
    PubMed     Text format     Abstract available


    November 2015
  19. PYKA T, Weirich G, Einspieler I, Maurer T, et al
    [68Ga]PSMA-HBED PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer.
    J Nucl Med. 2015 Nov 19. pii: jnumed.115.164442.
    PubMed     Text format     Abstract available


  20. LAFFON E, Burger IA, Lamare F, de Clermont-Gallerande H, et al
    SUVpeak performance in Lung Cancer: Comparison to Average SUV from 40 Hottest Voxels.
    J Nucl Med. 2015 Nov 12. pii: jnumed.115.161968.
    PubMed     Text format     Abstract available


  21. LUO H, England CG, Graves SA, Sun H, et al
    PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-labeled Ramucirumab.
    J Nucl Med. 2015 Nov 5. pii: jnumed.115.166462.
    PubMed     Text format     Abstract available


    October 2015
  22. SAWICKI LM, Grueneisen J, Buchbender C, Schaarschmidt BM, et al
    Evaluation of the outcome of lung nodules missed on 18F-FDG PET/MRI compared to 18F-FDG PET/CT in patients with known malignancies.
    J Nucl Med. 2015 Oct 29. pii: jnumed.115.162966.
    PubMed     Text format     Abstract available


  23. HUELLNER MW, Barbosa FG, Husmann L, Pietsch CM, et al
    TNM staging of NSCLC: Comparison of PET/MR and PET/CT.
    J Nucl Med. 2015 Oct 15. pii: jnumed.115.162040.
    PubMed     Text format     Abstract available


  24. ZHENG K, Liang N, Zhang J, Lang L, et al
    68Ga-NOTA-PRGD2 PET/CT for Integrin Imaging in Patients with Lung Cancer.
    J Nucl Med. 2015 Oct 1. pii: jnumed.115.160648.
    PubMed     Text format     Abstract available


  25. WEBER WA, Gatsonis C, Siegel B
    Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
    J Nucl Med. 2015;56:1636.
    PubMed     Text format    


  26. VAN DEN HOFF J, Hofheinz F
    Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV.
    J Nucl Med. 2015;56:1635-6.
    PubMed     Text format    


    September 2015
  27. VAN DER VOS CS, Grootjans W, Osborne DR, Meeuwis AP, et al
    Improving the spatial alignment in PET/CT using amplitude-based respiratory gated PET and respiratory triggered CT.
    J Nucl Med. 2015 Sep 17. pii: jnumed.115.163055.
    PubMed     Text format     Abstract available


    August 2015
  28. ZUBAL G
    From the Exhibitors' Hall: SNMMI Annual Meeting 2015.
    J Nucl Med. 2015;56:16N-19N.
    PubMed     Text format    


    June 2015
  29. KINAHAN PE, Mankoff D, Linden H
    The value of establishing the quantitative accuracy of PET/CT imaging.
    J Nucl Med. 2015 Jun 18. pii: jnumed.115.159178.
    PubMed     Text format    


  30. LUBBERINK M, Golla SS, Jonasson M, Rubin K, et al
    The water-perfusable tissue fraction of colorectal cancer metastases is increased by the selective PDGF-receptor inhibitor imatinib but not the IL-1 receptor antagonist anakinra, a study using serial dynamic 15O-water PET.
    J Nucl Med. 2015 Jun 11. pii: jnumed.114.151894.
    PubMed     Text format     Abstract available


    April 2015
  31. REUBI JC, Waser B
    Triple-peptide receptor targeting in vitro allows detection of all tested gut and bronchial NETs.
    J Nucl Med. 2015;56:613-5.
    PubMed     Text format     Abstract available


    February 2015
  32. FANCHON LM, Dogan S, Moreira AL, Carlin SA, et al
    Feasibility for in situ, High Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained under FDG PET/CT Guidance.
    J Nucl Med. 2015 Feb 26. pii: jnumed.114.148668.
    PubMed     Text format     Abstract available


  33. GURALNIK L, Rozenberg R, Frenkel A, Israel O, et al
    Metabolic PET/CT guided lung lesion biopsies - impact on diagnostic accuracy and rate of sampling error.
    J Nucl Med. 2015 Feb 19. pii: jnumed.113.131466.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: